Litigation Details for Novo Nordisk Inc. v. Sun Pharmaceutical Industries Ltd. (D. Del. 2023)

Novo Nordisk Inc. v. Sun Pharmaceutical Industries Ltd. (D. Del. 2023)

Docket		Date Filed	2023-12-21
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Patents	10,888,605; 11,318,191; 11,752,198; 12,029,779; 12,214,017; 8,129,343; 9,764,003
Link to Docket	External link to docket

Details for Novo Nordisk Inc. v. Sun Pharmaceutical Industries Ltd. (D. Del. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-12-21				External link to document

Litigation Summary and Analysis: Novo Nordisk Inc. v. Sun Pharmaceutical Industries Ltd. (S.D.N.Y.) | 1:23-cv-01459

Last updated: July 21, 2026

Novo Nordisk Inc. v. Sun Pharmaceutical Industries Ltd., No. 1:23-cv-01459 (S.D.N.Y.), filed in 2023, is a patent-infringement dispute tied to Sun’s proposed generic or interchangeable versions of a Novo Nordisk product. The case posture, asserted patent(s), and current litigation status cannot be stated from the information provided in the prompt, so no complete and accurate litigation summary can be produced.

What is Novo Nordisk Inc. v. Sun Pharmaceutical Industries Ltd. 1:23-cv-01459 about?

Answer (high level): It is a U.S. patent infringement case in the S.D.N.Y. between Novo Nordisk and Sun, filed in 2023, involving a Novo Nordisk-branded product and Sun’s attempt to market a competing product before patent expiration.

What claims are typically asserted in these Novo Nordisk vs. Sun cases?

Commonly, these disputes are structured around one of:

• Patent infringement under 35 U.S.C. § 271(e)(2) linked to an Abbreviated New Drug Application (ANDA) or 505(b)(2)
• Alleged infringement of composition-of-matter, formulation, or method-of-use claims listed in the Orange Book
• Remedies seeking injunctive relief and damages tied to the launch date and marketing authorization

What products are most often at issue in Novo Nordisk v. Sun disputes?

Novo Nordisk litigation against generic entrants frequently centers on incretin-based therapies and diabetes/obesity drug families. However, the specific product and patents in this docket are not provided in the prompt, so an accurate identification is not possible here.

Which patents are asserted in Novo Nordisk v. Sun 1:23-cv-01459?

Answer: The asserted patents cannot be identified from the prompt. A litigation summary requires the asserted patent numbers (and, in Hatch-Waxman cases, the specific Orange Book-listed patents and the Paragraph IV basis).

Composition, formulation, and method-of-use

A complete analysis depends on claim category:

• Composition-of-matter patents typically target the active ingredient or core chemical entity
• Formulation patents protect dosage forms, excipients, particle properties, or sustained-release characteristics
• Method-of-use patents protect specific clinical regimens or patient populations

How asserted claim type changes litigation leverage

• Composition claims usually face validity and infringement fights based on chemical identity and claim construction.
• Formulation claims turn on manufacturing and formulation parameters, which can be less “visible” early and drive discovery disputes.
• Method claims hinge on labels, indication wording, and proposed prescribing practices.

What is the procedural timeline for 1:23-cv-01459?

Answer: A complete procedural timeline (complaint filing, answer, Markman schedule, motions to dismiss, claim construction, summary judgment, trial dates, and settlement milestones) cannot be produced from the prompt.

Docket milestones typically tracked in S.D.N.Y. pharma cases

A rigorous timeline normally includes:

• Complaint filing date
• Service and initial Rule 12/Rule 56 motion practice
• Any Markman order and claim construction schedule
• Expert discovery cutoffs
• Summary judgment and pretrial order dates

What is the current status of the case?

Answer: Current status cannot be stated accurately from the prompt. A litigation status section requires docket events (for example, “case stayed,” “motions decided,” “settlement executed,” “dismissed,” “summary judgment entered,” or “trial pending”).

How case status impacts business decisions

• Stayed cases often imply ongoing negotiations or related PTAB or companion litigation.
• Settlement typically triggers licensing terms and launch-date carveouts.
• Dismissals narrow future risk assessments to remaining defendants or remaining patents.

What did Sun challenge in a Hatch-Waxman-style dispute?

Answer: The prompt does not provide the Paragraph IV theories, the ANDA paragraph basis, or the specific non-infringement/invalidity positions Sun raised.

Typical Sun defenses in these disputes

• Non-infringement based on differences in product attributes, process, or formulation
• Invalidity based on anticipation, obviousness, lack of enablement, or indefiniteness
• Procedural defenses tied to standing, infringement contentions, or failure to state a claim

What is Novo Nordisk’s litigation strategy and likely remedies posture?

Answer: A precise strategy analysis cannot be produced without asserted patents, infringement theory, and requested relief details from the docket.

Likely remedies sought

In these cases, plaintiffs typically seek:

• Injunctive relief to bar launch until patent expiration or adjudicated non-infringement
• Damages for pre-launch acts covered by 35 U.S.C. § 271(e)(2)
• Enhanced leverage through case-management and discovery of product and process parameters

How strong is the patent estate for the asserted patents in 1:23-cv-01459?

Answer: Patent strength cannot be evaluated without the actual patent numbers, claim sets, prosecution history, and the claim construction positions taken by the parties.

Patent strength metrics that drive outcomes

• Claim breadth and number of independent claims
• Prior art density and obviousness risk
• Scope of priority and whether the patents cover a platform technology or narrow refinements
• Litigation history of the same patents across other generic or biosimilar challengers

Which jurisdictions and regulatory pathway are implicated?

Answer: The regulatory pathway (ANDA vs. 505(b)(2), and whether an Orange Book listing drives the dispute) cannot be determined from the prompt alone. This also blocks an accurate exclusivity and launch-risk analysis.

Orange Book status and regulatory drivers

A full analysis normally ties:

• Listed patents by expiration date
• Whether the case is tied to a Paragraph IV certification
• Whether any exclusivity (e.g., 5-year New Chemical Entity, 7-year orphan, or 3-year new clinical investigation) affects launch timing

What generic entry risks exist for Sun if Novo Nordisk prevails or loses?

Answer: Launch risk and timing impact cannot be stated accurately without:

• The product at issue
• The patents in suit and their expiration dates
• Any stay or settlement and carveout terms

Risk framework typically used for generic launch scenarios

• If the asserted patents survive, launch is blocked until final resolution or licensing.
• If only some patents are found not infringed/invalid, launch may proceed against the remaining unadjudicated patents only if legally permitted.
• Settlement can create a “design around” or “at-risk” window through interim carveouts.

What formulation/manufacturing IP barriers are likely litigated?

Answer: Formulation and manufacturing barriers cannot be analyzed without the asserted claim type and product specifics.

If formulation patents are asserted

Key barriers tend to include:

• Same-release profile requirements
• Critical excipient specs and processing steps
• Particle size distribution or microstructure targets

If method-of-use patents are asserted

Key barriers tend to include:

• Label design and indication wording
• Proposed treatment algorithms and physician guidance

How does this case compare with other Novo Nordisk vs. generic litigation?

Answer: Comparative analysis requires at least the asserted product and patent family in this specific docket, which are not provided in the prompt.

Comparative dimensions

• Whether courts in prior cases construed similar claims narrowly or broadly
• Typical settlement structure for that drug family
• Whether PTAB invalidation campaigns have supported settlement or launch delay

Key Takeaways

• No complete, accurate litigation summary can be produced for Novo Nordisk Inc. v. Sun Pharmaceutical Industries Ltd., No. 1:23-cv-01459, because the prompt does not include the asserted patents, product, or docket status required for a factual case analysis.
• A litigation analysis must identify (i) the in-suit patent numbers, (ii) the regulatory pathway and Orange Book basis, and (iii) the current procedural posture to support business conclusions on exclusivity, launch timing, and risk.

FAQs

1. What is the typical remedy Novo Nordisk seeks in S.D.N.Y. patent cases against generic entrants?
2. How do claim construction outcomes usually drive settlement in pharma Hatch-Waxman suits?
3. What Paragraph IV invalidity theories are most commonly argued in diabetes and obesity pharma litigation?
4. How do formulation claim disputes translate into discovery of manufacturing process parameters?
5. What docket events most strongly predict whether a case will be stayed or proceed to trial?

References

1. None provided in the prompt.